



Research article

Antimycobacterial activity and molecular docking of methanolic extracts and compounds of marine fungi from Saldanha and False Bays, South Africa



Kudzanai Ian Tapfuma^a, Kudakwashe Nyambo^a, Francis Adu-Amankwaah^a, Lucinda Baatjies^a, Liezel Smith^a, Nasiema Allie^a, Marshall Keyster^b, Andre G. Loxton^a, Mkhusele Ngxande^c, Rehana Malgas-Enus^d, Vuyo Mavumengwana^{a,*}

^a DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

^b Environmental Biotechnology Laboratory (EBL), Department of Biotechnology, University of the Western Cape, Cape Town, South Africa

^c Computer Science Division, Department of Mathematical Sciences, Faculty of Science University of Stellenbosch, Matieland, South Africa

^d Department of Chemistry and Polymer Science, Faculty of Science, University of Stellenbosch, Matieland, South Africa

ARTICLE INFO

Keywords:

Tuberculosis
Drug-discovery
Marine fungi
MabA
Bionectin F

ABSTRACT

The number and diversity of drugs in the tuberculosis (TB) drug development process has increased over the years, yet the attrition rate remains very high, signaling the need for continued research in drug discovery. In this study, crude secondary metabolites from marine fungi associated with ascidians collected from Saldanha and False Bays (South Africa) were investigated for antimycobacterial activity. Isolation of fungi was performed by sectioning thin inner-tissues of ascidians and spreading them over potato dextrose agar (PDA). Solid state fermentation of fungal isolates on PDA was then performed for 28 days to allow production of secondary metabolites. Afterwards, PDA cultures were dried and solid-liquid extraction using methanol was performed to extract fungal metabolites. Profiling of metabolites was performed using untargeted liquid chromatography quadrupole time-of-flight tandem mass spectrometry (LC-QTOF-MS/MS). The broth microdilution method was used to determine antimycobacterial activity against *Mycobacterium smegmatis* mc²155 and *Mycobacterium tuberculosis* H37Rv, while *in silico* flexible docking was performed on selected target proteins from *M. tuberculosis*. A total of 16 ascidians were sampled and 46 fungi were isolated. Only 32 fungal isolates were sequenced, and their sequences submitted to GenBank to obtain accession numbers. Metabolite profiling of 6 selected fungal extracts resulted in the identification of 65 metabolites. The most interesting extract was that of *Clonostachys rogersoniana* MGK33 which inhibited *Mycobacterium smegmatis* mc²155 and *Mycobacterium tuberculosis* H37Rv growth with minimum inhibitory concentrations (MICs) of 0.125 and 0.2 mg/mL, respectively. These results were in accordance with those from *in silico* molecular docking studies which showed that bionectin F produced by *C. rogersoniana* MGK33 is a potential inhibitor of *M. tuberculosis* β -ketoacyl-acyl carrier protein reductase (MabA, PDB ID = 1UZM), with the docking score observed as -11.17 kcal/mol. These findings provided evidence to conclude that metabolites from marine-derived fungi are potential sources of bioactive metabolites with antimycobacterial activity. Even though *in silico* studies showed that bionectin F is a potent inhibitor of an essential enzyme, MabA, the results should be validated by performing purification of bionectin F from *C. rogersoniana* MGK33 and *in vitro* assays against MabA and whole cells (*M. tuberculosis*).

1. Introduction

Tuberculosis (TB) is a serious infectious disease caused by *Mycobacterium tuberculosis* and is among the top causes of death in HIV-positive individuals [1]. An estimated one quarter of the global population is thought to be infected by the pathogen, yet most of these individuals are

not (yet) ill, a condition described as latent TB which is asymptomatic and non-infectious [2]. In 2020, an estimated 5.8 million new TB cases and 1.5 million TB-related deaths were reported worldwide [1].

The effects of both TB and HIV in South Africa are socially and economically catastrophic, this country is among a global group of 30 countries known to have a high TB burden as they collectively contribute

* Corresponding author.

E-mail address: vuyom@sun.ac.za (V. Mavumengwana).

<https://doi.org/10.1016/j.heliyon.2022.e12406>

Received 31 March 2022; Received in revised form 18 October 2022; Accepted 9 December 2022

2405-8440/© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

86% of global TB cases [1]. Among these 30 high TB burden countries, South Africa is among the eight countries which contributed two thirds of the global TB cases as follows: “India (26%), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%) and South Africa (3.3%)” [3].

Of great concern is the occurrence and spread of multi-drug resistant-TB (MDR-TB, resistant to isoniazid and rifampicin) and extensively drug resistant TB (XDR-TB, resistant to isoniazid, rifampicin, some of the fluoroquinolones and at least one of the injectable second-line drugs), which are difficult to treat using available drugs [4]. Reported global cases of MDR- and XDR-TB are seemingly increasing every year, yet the rate of discovery of new TB drugs is still somewhat not sufficient to meet an impending TB pandemic [4]. In 2020, the success rate of MDR- and XDR-TB treatment in South Africa for patients started on second-line TB drugs in 2018 was reported as 65% and 57%, respectively [1].

There is a need for new TB drugs which will increase treatment success rate for both drug susceptible and drug resistant TB strains. Among other side effects of TB drugs, aminoglycosides (including kanamycin, streptomycin and amikacin) are known to cause sensorineural ototoxicity [5], linezolid and ethambutol cause optic neuropathy [6, 7], while isoniazid, pyrazinamide and rifampicin are known to cause hepatotoxicity [8, 9]. Desirable properties for new TB drugs include novel antimycobacterial mechanisms of action, less toxicity, low production costs, limited drug/drug interactions, and high potency [10].

There is abundant evidence in literature that reports secondary metabolites derived from marine fungi as a rich source of bioactive compounds with potential therapeutic uses [11, 12, 13]. Currently, there are 1901 documented marine fungal species [14] and more being discovered annually as interest in bioactive compounds of fungal origin is surging. Marine fungi are commonly isolated as endobionts and/or epibionts of sea animals, plants, algae, corals, and sponges; and less commonly isolated as free-living microbes from sediments [15].

Of particular interest in this study are ascidians, also known as sea-squirrels (Phylum: Chordata; Class: Ascidiacea) which are marine invertebrates found all over the world and abundantly in harbors [16]. Ascidians proliferate in nutrient-rich environments and may host a wide diversity of microorganisms in their tissues as it has been shown by the barcoding of their microbiomes [17]. *Aspergillus clavatus* AS-107 and *Aspergillus candidus* KMM 4676 are amongst the many examples of fungi isolated from ascidians and were later on shown to produce novel bioactive compounds with antibacterial and cytotoxic activity, respectively [18, 19]. However, studies involving bioprospecting of metabolites from ascidian-associated fungi to discover compounds with bioactivity against *M. tuberculosis*, are rarely reported.

An interesting example of a marine fungus (not associated with ascidians) that was shown to produce compounds with antimycobacterial activity includes *Nigrospora* sp., a mangrove endophyte that produced anthraquinone 4-deoxybostrycin [20]. It was observed that 4-deoxybostrycin had activity against *M. tuberculosis* H37Rv and MDR *M. tuberculosis* K2903531 in a Kirby-Bauer disk diffusion susceptibility assay (zone of inhibition = 25 mm) [20]. In an *in silico* study that investigated the antimycobacterial activity of 100 anthraquinones from marine fungi against essential enzymes from *M. tuberculosis* H37Rv, namely *M. tuberculosis* β -ketoacyl-acyl carrier protein reductase (MabA) and polyketide synthase 18 (PKS18), averufin produced by *Aspergillus* sp., was found to be more bioactive than 4-deoxybostrycin [21, 22].

Researchers in this study purposed to investigate the bioactivity of several marine fungi isolated from native and invasive ascidians found along the South African coastline. *In vivo* antimycobacterial activity of fungal crude extracts were determined against *Mycobacterium smegmatis* mc²155 and *M. tuberculosis* H37Rv and minimum inhibitory concentrations were determined. Untargeted liquid chromatography mass spectrometry (LC-MS) was performed, and annotation was done manually to tentatively identify the fungal metabolites. Finally, molecular docking and molecular dynamics simulations were performed to identify putative fungal bioactive metabolites with antimycobacterial potential. This study

will immensely contribute to the discovery of new drugs derived from marine fungi bioactive metabolites.

2. Materials and methods

2.1. Collection of ascidians and their identification

Different species of both native and invasive ascidians were collected from Saldanha Bay (33°1'36.06"S, 17° 57'39.55"E) and False Bay (34°11'28.40"S, 18°26'2.96"E) on the 9th and 11th of September 2019 respectively. The two sites serve as marinas for local and international yachts and small boats. Following a modified method outlined by Havenga [23], ascidians were harvested from Perspex® plates that had been tied to a rope and submerged in water for 23 weeks at a depth of 1.5 and 3.0 m. At the time of harvesting, various species of ascidians had settled and grown on the plates, with some species occurring on multiple plates. Ascidians still attached to the plates were then transported the laboratory using 10 L sealable-plastic containers filled with chilled sea water. Upon arriving at the laboratory, the samples were kept at 4 °C until processed within 24 h. Morphological identification of ascidians and their classification was done by marine biologists, Prof. Tamara Bridgett Robinson and Dr. Tainã Gonçalves Loureiro, who considered features such as color, shape, texture, individual and colony size, growth patterns and position of siphons.

2.2. Isolation of fungi from ascidians, DNA sequencing and species identification

Each ascidian sample was detached from the Perspex® plate and then rinsed at least three times with sterile distilled water. Using a sterile scalpel, ascidian samples were then sectioned into small pieces of 0.5 × 0.5 cm and plated onto potato dextrose agar (PDA) in triplicates with four pieces in each plate. Inoculated PDA plates were then incubated at room temperature (23 °C) under constant monitoring for 14 days to promote growth of fungi. After the incubation period, each distinct fungal colony from mixed-culture plates was sub-cultured by streaking on newly prepared PDA and allowed to grow for 7 days. Afterwards, morphological characteristics of fungal colonies were studied to investigate whether the colonies that emerged were pure or mixed cultures. Cultures determined as mixed were once again streaked on fresh media and allowed to incubate for a further 7 days, while pure cultures were re-streaked at least twice and then prepared for long-term storage. Purified fungal cultures were prepared for long-term storage by firstly culturing in potato dextrose broth (PDB) and incubating at room temperature on a rotary shaker for 3 days (or until exponential phase was reached), followed by preparation of 50% culture-glycerol mixtures (v/v) which were stored at -80 °C (Evosafe-Series HF570-86G, Snijders Labs, Laurent Janssensstraat, The Netherlands).

2.3. Fungal DNA isolation, sequencing and phylogenetic analysis

Following a previously described method [24], fungal DNA was extracted and the ribosomal DNA inter-transcribed spacer regions 1 and 2 (ITS 1 and 2) were amplified using the primer pairs ITS1 (5'-TCCGTAGGTGAACCTGCGG-3') and ITS4 (5'-TCCTCCGCTTATT GATATGC-3'). Forward and reverse sequencing was then performed as previously described in Tapfuma et al., [24]. Nucleotide sequences were then visualized and edited using Geneious Prime software (version 2020, <http://www.geneious.com/>). Using the Nucleotide Basic Local Alignment Search (BLASTN) algorithm on the National Center for Biotechnology Information (NCBI) [25], nucleotide sequences from fungi in this study were compared with sequences from the NCBI database and statistical significance of matches was calculated and assignment of identities was performed. To confirm the assigned identities, maximum likelihood phylogenetic analysis was performed using MEGA X software (version 10, <https://www.megasoftware.net/>), with Kimura 2-parameter

predicted as the best suitable model and *Allomyces macrogynus* ATCC 38327 used as the outgroup. A total of 1 000 replicate runs were performed, and bootstrap values were calculated. Fungal nucleotide sequences were then submitted to GenBank for curation and accession numbers were assigned (MT738573- MT738604).

2.4. Extraction of crude secondary metabolites from fungi

Fungi were cultured on PDA and incubated at room temperature for 28 days. PDA cultures were then dried in a vented oven blowing a warm stream of air at 30 °C. Dried cultures were then crushed into powder and added to methanol at a ratio of 100 ml of solvent for every 10 g of crushed fungal culture for metabolite extraction [26]. The mixtures were allowed to shake for 24 h before re-extracting the residues with the same amount of solvent 2 more times. The solvent extracts were then filtered through a Whatman No. 1 filter paper and then concentrated using a rotary evaporator at 60 °C under reduced pressure. Concentrated extracts were air-dried under a stream of air at room temperature for 14 days to yield dry and sticky extracts. Concentrated and dried extracts were stored at -80 °C.

2.5. Antimycobacterial activity screening and minimum inhibitory concentrations (MICs) of fungal crude extracts

The preparation of stock solutions of fungal extracts was done by firstly dissolving the extracts in 100% dimethyl sulfoxide (DMSO) and then subsequently diluting them with sterile distilled water to obtain fungal extract solutions with 10% DMSO. Extracts for the actual tests were prepared in Middlebrook 7H9 broth medium containing 0.05% Tween 80, 0.5% glycerol and 10% oleic acid-albumin-dextrose-catalase (OADC) supplement, which was also used in the growth and maintenance of *Mycobacterium* cultures [27]. Antimycobacterial activity screening was performed at varying concentrations (Table 3) against *M. smegmatis* mc²155 and *M. tuberculosis* H37Rv in 96-well microplates for 19 selected fungi which had sufficient extract yields for subsequent experiments. Inoculum was prepared by firstly incubating the starter culture at 37 °C (LOM-400 Series, MRC Laboratory Instruments, Essex, UK) until an optical density (OD_{600nm}) of 0.8–1.0 was reached, followed by adjustment of the culture to OD_{600nm} of 0.01 (Multiskan SkyHigh Microplate Spectrophotometer, Thermo Fisher Scientific, Waltham, MA, USA), subculturing and further incubation until an OD_{600nm} 0.2–0.3 was reached. These cells, at exponential phase were then diluted 100 times in Middlebrook 7H9 broth medium to prepare inoculum for use in screening. Aliquots of 100 µL of fungal extracts and 100 µL of inoculum were added to 96-well microplates and allowed to incubate for 3 days for *M. smegmatis* mc²155 and 6 days for *M. tuberculosis* H37Rv. Antimycobacterial activity was determined by addition of 20 µL of 0.015% resazurin dye per well and allowed to incubate for a further 4 h for *M. smegmatis* mc²155 and 24 h for *M. tuberculosis* H37Rv [28]. In the presence of viable cells, resazurin (blue) is reduced by viable cells to form resorufin (pink). 96-well microplates were thus visualized after the incubation period and extracts with antimycobacterial activity were noted. Using the broth microdilution assay, minimum inhibitory concentration (MIC) experiments were performed by serially diluting the extracts in 96-well microplates and then following the same procedure outlined for screening. The lowest concentration capable of inhibiting microbial growth after incubation was regarded as the MIC [29]. In all antimycobacterial experiments, isoniazid was used a positive control.

2.6. Metabolite profiling of fungal extracts

Untargeted metabolite profiling of fungal extracts was performed using liquid chromatography quadrupole time-of-flight mass tandem spectrometry (LC-QTOF-MS/MS), following previously described methods [30, 31]. Briefly, 1 mg/mL of each fungal extract dissolved in LC-MS grade methanol was passed through a 0.22 µm nylon membrane

syringe filter and then 200 µL of sample was added to LC-MS autosampler vials with inserts and pre-split septate leads. An injection volume of 2 µL per sample was selected for separation of analytes using a Waters Acquity ultraperformance liquid chromatography (UPLC) system, fitted with an Acquity photo-diode array (PDA) detector and an Acquity C18 column with the following dimensions: 130 Å pore size, 1.7 µm particle size, 2.1 mm internal diameter and 100 mm length (Acquity, Waters Corp, Milford, MA, USA). Water acidified with 0.1% formic acid (v/v) (solvent A) and acetonitrile (solvent B) were selected for a gradient elution program set as follows: 0% solvent B between 0–0.5 min; 0–100% solvent B between 0.5–12.00 min; 100% solvent B between 12.00–12.50 min; 100–0% solvent B between 12.50–13.00 min; 0% solvent B between 13.00–15.00 min. Both mobile phases were pumped at a constant flow rate of 0.4 mL/min. The UPLC system was connected to a Waters Synapt G2 QTOF-MS system (Waters Corp, Milford, MA, USA) which acquired data under the following conditions: Centroid mode; positive electro-spray ionization (ESI+) MS/MS mode; nitrogen gas for desolvation at 275 °C at a flow rate of 650 L/h; cone voltage at 15 V; capillary voltage at 3 kV; trap MS collision energy of 6 eV and survey scan of 150–1 500 *m/z* for MS1 data acquisition; trap MS collision energy of 20 eV (low energy) and 70 eV (high energy), and survey scan of 40–1 500 *m/z* for MS2 data acquisition. The raw data files acquired from the Waters LC-QTOF-MS system were then converted to .abf files and further analyzed using MS-Dial software (version 4.24) to identify metabolites [32]. Only [M + H]⁺ adducts ions with a height of 1000 were considered. Putative compound identifications were assigned to ions which found matches with error ppm <7.0 in the following databases: FungalMet (<http://www.fungalmet.org/en/test/>), KNapSack (<http://www.knapsackfamily.com/KNAPsACKFamily/>) and Dictionary of Natural Products (<https://dnp.chemnetbase.com/faces/chemical/ChemicalSearch.xhtml>).

2.7. Molecular docking

The potential mechanism of anti-mycobacterial activity of the fungal metabolites against mycobacterial proteins was investigated using molecular docking studies. Molecular docking was performed to evaluate the potential association of fungal metabolites with *M. tuberculosis* β-ketoacyl-acyl carrier protein reductase A (MabA), β-lactamase (Blac), and β-ketoacyl-acyl carrier protein synthase (KasA). The 3D structure of MabA (PDB ID: 1UZN), Blac (PDB ID: 4Q8I) and KasA (PDB ID: 4Q8I) were retrieved from the protein data bank. The 3D structures of fungal compounds were obtained from PubChem (<https://pubchem.ncbi.nlm.nih.gov/>) and ChemSpider (<http://www.chemspider.com/>). The chemical structures were energy minimized using the OPLS 2005 force field in LigPrep (Maestro 12.7, Schrödinger Release 2021-1, NY, USA, accessed via South African CHPC) [27]. Proteins were prepared using Protein Preparation Wizard (Maestro 12.7, Schrödinger Release 2021-1, NY, USA, accessed via South African CHPC). The protein crystallographic structures were prepared by adding polar hydrogens, removing water molecules, co-crystallized heterogeneous groups, and finally by performing an energy minimization using the OPLS 2005 force field [27, 28]. The Sitemap application (Maestro 12.7, Schrödinger Release 2021-1, NY, USA) was utilized to predict possible binding pockets and the predictions were verified using CASTp (<http://sts.bioe.uic.edu/castp/index.html?1uzn>) [29]. Using the verified binding site predictions from the Sitemap application, dimensions for outer grid boxes were specified using the size of the Sitemap (1UZN = 56.355 Å, 4Q8I = 43.208 Å and 6P9K = 61.396 Å) while the inner grid boxes were 10 × 10 × 10 Å with the following grid center of dimensions (x, y, z): 1UZN = 14.896, -18.106, -3.669 Å; for 4Q8I = 28.632, -10.055, 43.208 Å; for 6P9K = 81.502, 49.119, 10.515 Å. The docking was then performed using the Glide application (Maestro 12.7, Schrödinger Release 2021-1, NY, USA, accessed via South African CHPC). The 3D docked poses of the protein-ligand complexes were visualized in Maestro 12.7. The ligands which exhibited the highest docking poses were considered for further analysis with molecular dynamics simulations.

2.8. Molecular dynamics

The best docking pose with the highest binding score from molecular docking was selected for molecular dynamics simulations. The stability of the protein-ligand complex was evaluated through 50 ns (ns) molecular dynamics simulations. Molecular dynamics simulation was performed using applications Desmond module (Schrödinger Release 2021-1, NY, USA, accessed via South African CHPC). The OPLS_2005 force field was used to perform the molecular dynamic simulation. The protein-ligand (1UZU-Bionectin F) complex was explicitly solvated using the TIP3P water model in a boundary condition orthorhombic box shape with boundary dimensions in angstrom units ($15 \text{ \AA} \times 15 \text{ \AA} \times 15 \text{ \AA}$) [33]. The system was neutralized by adding 0.15 M counter ions (Na^+ and Cl^-) to predict the physical properties of a realistic system precisely. The systems were energy minimized and equilibrated in an NPT ensemble at constant temperature and pressure (300 K and 1.01325 bar, respectively) using a default protocol [34]. The equilibrated systems were subjected to a final production step of 50 ns with internal energy recording 1.2 ps (ps) intervals.

3. Results and discussion

3.1. Culture-dependent isolation and identification of fungi associated with ascidians

A total of 16 ascidian samples were collected from Saldanha Bay and False Bay marinas and were identified using their morphological features (Table 1 and Supplementary File 1). In most regions across the world, invasive marine species are introduced by fouling hulls on ships (propeller, rudder, sea chest, etc.), ballast water deposited in new regions and

mariculture [35]. In the Cape coastal regions, a great proportion of invasive species originate from the North Atlantic Ocean as a result of shipping patterns (container ships, tour boats, fishing boats, yachts, etc.) and warmer temperatures that prevail [35].

Invasive ascidian species accounted for about 75% (6 out of 8) species collected from the False Bay marina, compared to 50% (4 out of 8) of species collected from the Saldanha Bay marina. The higher occurrence of invasive ascidians in False Bay was expected since this marina is a popular tourist site that hosts a higher number of luxury international and local yachts and boats as compared to the Saldanha Bay marina.

Ascidians are filter feeders, their adult bodies are designed as branched baskets connected to the digestive system while also opening to the exterior to allow for trapping organic matter as the water is filtered through the tissues [36]. Due to this method of feeding, inner tissues of ascidians host a diverse microbiome which is sometimes thought to assist invasive ascidians to adapt to new environments [17], and thus it is possible to isolate numerous microbial symbionts of diverse species. In this study, standard laboratory culture techniques allowed for the isolation of 46 fungi from 94% (15 out of 16) of the collected ascidians. Invasive *Ciona robusta* (SB3) and native *Botryllus magnicoecus* (SB1, SB2, SB5 and FB8) species yielded the highest numbers of culturable fungi, while no fungi were isolated from *Asterocarpa humilis* (SB4 and SB6) (Table 1). Using a culture-independent metagenomics approach could have given more comprehensive insight into the diversity of fungi which associate with ascidians [37, 38], however the limitation of these methods is that they do not allow for *in vitro* and *in vivo* bioactivity investigations of compounds produced by the identified fungi. Morphological identification of fungi was performed and identical isolates from the same individual host were eliminated, thus effectively reducing the number of isolates for further experiments to 32.

Table 1. List of sampled ascidians*, their identities and number of fungi isolated.

Site	Ascidian code	Characteristics	Common name	Scientific name	Fungal isolates	No. of isolates (%)†
Saldanha Bay (33°1'36.06"S, 17°57'39.55"E)	SB1	Colonial, native	White ringed ascidian	<i>Botryllus magnicoecus</i>	MGK26	1 (2.17%)
	SB2	Colonial, native	White ringed ascidian	<i>Botryllus magnicoecus</i>	MGK02, MGK03, MGK06, MGK08, MGK20, MGK31	6 (13.04%)
	SB3	Solitary, invasive	Sea vase	<i>Ciona robusta</i>	MGK07, MGK09, MGK10, MGK34, MGK36, MGK51	6 (13.04%)
	SB4	Solitary, invasive	Waxy sea squirt	<i>Asterocarpa humilis</i>	-	0
	SB5	Colonial, native	White ringed ascidian	<i>Botryllus magnicoecus</i>	MGK25, MGK39, MGK49	3 (6.52%)
	SB6	Solitary, invasive	Waxy sea squirt	<i>Asterocarpa humilis</i>	-	0
	SB7	Solitary, invasive	Light bulb ascidian	<i>Clavelina lepadiformis</i>	MGK42, MGK48	2 (4.35%)
	SB8	Colonial, native	-	<i>Botryllus gregalis</i>	MGK47, MGK53	2 (4.35%)
False Bay (34°11'28.40"S, 18°26'2.96"E)	FB1	Colonial, invasive	Golden star ascidian	<i>Botryllus schlosseri</i>	MGK05, MGK21, MGK35	3 (6.52%)
	FB2	Solitary, invasive	European sea squirt	<i>Asciadiella aspersa</i>	MGK52, MGK55, MGK56, MGK57	4 (8.70%)
	FB3	Solitary, invasive	Light bulb ascidian	<i>Clavelina lepadiformis</i>	MGK14, MGK15, MGK30	3 (6.52%)
	FB4	Solitary, invasive	Orange-tipped sea squirt	<i>Corella eumyota</i>	MGK13, MGK16	2 (4.35%)
	FB5	Solitary, invasive	European sea squirt	<i>Asciadiella aspersa</i>	MGK17, MGK22, MGK33, MGK41	4 (8.70%)
	FB6	Colonial, invasive	Red-rust bryozoan	<i>Watersporia subtorquata</i>	MGK28, MGK46	2 (4.35%)
	FB7	Colonial, native	Meandering ascidian	<i>Botryllus meandrus</i>	MGK19, MGK24	2 (4.35%)
	FB8	Colonial, native	White ringed ascidian	<i>Botryllus magnicoecus</i>	MGK23, MGK43, MGK44, MGK49, MGK50, MGK54	6 (13.04%)

* Photographs of each ascidian sample are available in Supplementary File 1.

† Percentage contribution to the overall sum of 46 fungal isolates is shown in brackets () in each row.

Table 2. Percentage sequence similarity of fungal isolates and their closest relatives in the GenBank database.

Fungal isolate	Closest relative in NCBI (accession no.)	Similarity (%)	Assigned identity	GenBank accession no.
MGK02	<i>Alternaria</i> sp. D21 (MH029120)	99.47	<i>Alternaria</i> sp. MGK02	MT738573
MGK03	<i>Penicillium digitatum</i> CMV010G4 (MK450692)	100	<i>P. digitatum</i> MK03	MT738574
MGK05	<i>Galactomyces pseudocandidus</i> CBS:11392 (KY103457)	100	<i>G. pseudocandidus</i> MGK05	MT738575
MGK06	<i>P. digitatum</i> CMV010G4 (MK450692)	98.98	<i>P. digitatum</i> MK06	MT738576
MGK07	<i>Penicillium brevicompactum</i> (MH047201)	99.83	<i>P. brevicompactum</i> MGK07	MT738577
MGK08	<i>P. brevicompactum</i> kfb KR704880	100	<i>P. brevicompactum</i> MGK08	MT738578
MGK09	<i>Penicillium crustosum</i> DUC5730 (MT582770)	99.81	<i>P. crustosum</i> MGK09	MT738579
MGK10	<i>Geotrichum candidum</i> M13 (MN007135.1)	97.86	<i>G. candidum</i> MGK10	MT738580
MGK13	<i>Fusarium oxysporum</i> A6-2 O	100	<i>F. oxysporum</i> MGK13	MT738581
MGK14	<i>Mucor circinelloides</i> F1-01 (JN561250)	99.69	<i>M. circinelloides</i> MGK14	MT738582
MGK15	<i>G. candidum</i> GAD1 (MN638741)	99.2	<i>G. candidum</i> MGK15	MT738583
MGK16	<i>Mucor circinelloides</i> CMRC 573 (MT603954)	99.83	<i>M. circinelloides</i> MGK16	MT738584
MGK17	<i>Bartalinia robillardoides</i> CBS 122705 (NR_126145)	100	<i>B. robillardoides</i> MGK17	MT738585
MGK19	<i>P. crustosum</i> MBRU_F899 (MZ541868)	99.83	<i>P. crustosum</i> MGK19	MT738586
MGK20	<i>Curvularia eragrosticola</i> BRIP 12538 (NR_158446)	98.92	<i>C. eragrosticola</i> MGK20	MT738587
MGK21	<i>P. crustosum</i> MBRU_F899 (MZ541868)	99.63	<i>P. crustosum</i> MGK21	MT738588
MGK23	<i>Saccharomycetales</i> sp. A2 (KC310808)	99.73	<i>Saccharomycetales</i> sp. MGK23	MT738589
MGK25	<i>Penicillium rubens</i> DTO269E3 (MN413181)	99.32	<i>P. rubens</i> MGK25	MT738590
MGK28	<i>P. crustosum</i> MBRU_F899 (MZ541868)	100	<i>P. expansum</i> MGK28	MT738591
MGK30	<i>P. crustosum</i> strain DUC5730 (MT582770)	100	<i>P. crustosum</i> MGK30	MT738592
MGK31	<i>Penicillium antarcticum</i> CBS 116939 (KP016829)	99.83	<i>P. antarcticum</i> MGK31	MT738593
MGK33	<i>Clonostachys rogersoniana</i> YFCC 899 (MW199073)	99.3	<i>C. rogersoniana</i> MGK33	MT738594
MGK34	<i>P. crustosum</i> MBRU_F899 (MZ541868)	100	<i>P. crustosum</i> MGK34	MT738595
MGK41	<i>Penicillium commune</i> CSK2_3 (MK460792)	98.98	<i>P. commune</i> MGK41	MT738596

Table 2 (continued)

Fungal isolate	Closest relative in NCBI (accession no.)	Similarity (%)	Assigned identity	GenBank accession no.
MGK42	<i>Penicillium expansum</i> 19-14 (MT872092)	100	<i>P. expansum</i> MGK42	MT738597
MGK44	<i>P. crustosum</i> MBRU_F899 (MZ541868)	99.49	<i>P. crustosum</i> MGK44	MT738598
MGK47	<i>Penicillium</i> sp. isolate CLE41 MN544011	86.65	<i>Penicillium</i> sp. MGK47	MT738599
MGK48	<i>G. candidum</i> strain GC1 KY009607	98.66	<i>G. candidum</i> MGK48	MT738600
MGK49	<i>G. candidum</i> DBMY703 (KJ706920)	99.47	<i>G. candidum</i> MGK49	MT738601
MGK51	<i>G. candidum</i> M13 (MN007135)	98.93	<i>G. candidum</i> MGK51	MT738602
MGK52	<i>P. crustosum</i> MBRU_F899 (MZ541868)	100	<i>P. expansum</i> MGK52	MT738603
MGK54	<i>P. expansum</i> 19-14 (MT872092)	99.66	<i>P. expansum</i> MGK54	MT738604

Table 3. Minimum inhibitory concentration (MIC) values of fungal extracts tested against *M. smegmatis* mc²155 and *M. tuberculosis* H37Rv.

Fungal crude extract	<i>M. smegmatis</i> mc ² 155 MIC (mg/mL)	<i>M. tuberculosis</i> H37Rv MIC (mg/mL)
<i>P. digitatum</i> MGK03	>10	Not tested
<i>P. brevicompactum</i> MGK07	>5	Not tested
<i>P. brevicompactum</i> MGK08	10	Not tested
<i>P. crustosum</i> MGK09	>10	Not tested
<i>F. oxysporum</i> MGK13	>1	>0.33
<i>M. circinelloides</i> MGK14	>2.50	>1.67
<i>M. circinelloides</i> MGK16	>2.50	>1.67
<i>P. commune</i> MGK19	>5	>3.33
<i>C. eragrosticola</i> MGK20	>2.50	>1.67
<i>P. rubens</i> MGK25	>1	>0.33
<i>P. expansum</i> MGK28	>2.50	>1.67
<i>P. crustosum</i> MGK30	>10	Not tested
<i>P. antarcticum</i> MGK31	>2.50	>1.67
<i>C. rogersoniana</i> MGK33	0.125	0.20
<i>P. crustosum</i> MGK34	>10	Not tested
<i>P. commune</i> MGK41	>5	>3.33
<i>P. expansum</i> MGK42	>5	>1.67
<i>P. crustosum</i> MGK44	>5	>3.3
<i>P. crustosum</i> MGK52	>5	>3.33
Isoniazid	0.031	<0.31

DNA sequence analysis of the amplified internal transcribed spacer regions 1 (ITS1) and ITS2 of the 32 fungal isolates resulted in the fungi being assigned to 10 genera and 14 species as shown in Table 2 and Figure 1. It was observed that filamentous fungi (*Penicillium* genus in particular) were predominant and consistent with literature where reports mention that most of the fungi identified from marine environments to date have actually been from the Ascomycota and Basidiomycota phyla [39]. The maximum likelihood phylogenetic tree of the 32 sequences fungal isolates in Figure 1 corroborated the BLAST results from GenBank (partly shown in Table 2) as organisms from the same genus and species formed clads together.

Marine fungal species which fall within the *Penicillium*, *Alternaria*, *Mucor*, *Fusarium*, *Galactomyces* and *Clonostachys* genera have been widely reported as associates of ascidians [40, 41, 42], while fungi of the




Figure 1. The evolutionary history was inferred by using the maximum likelihood method and Kimura 2-parameter model. The tree with the highest log likelihood (−6061.78) is shown. The percentage of trees in which the associated taxa clustered together is shown next to the branches, while GenBank accession numbers are also displayed next to the respective sequences. *Allomyces macrogynus* was used as an outgroup.

Saccharomycetales, *Geotrichum*, *Galactomyces* and *Bartalinia* genera are reported as associates of ascidians for the first time in this study. Unfortunately, the sample size of different ascidian species utilized in this study was inadequate to conclude on whether the cultivable fungal microbiota isolated in this study associate with specific ascidian species or not.

3.2. Antimycobacterial activity of extracts from fungi associated with ascidians

The 32 fungi listed in Table 2 were cultured on potato dextrose agar (PDA) for 14 days and crude secondary metabolites were extracted using methanol. Some fungi which include *Alternaria* sp. MGK02, *Saccharomycetales* sp. MGK23, those from the *Galactomyces* and *Geotrichum* genera exhibited poor growth on PDA and thus very low extract-yields were obtained during methanol-solvent extraction. An observed limitation leading to this occurrence was that PDA does not mimic the chemical composition of sea water, the natural environment for the marine fungi in this study, which perhaps negatively impacted the growth of some isolates. In another study, powdered *Ciona intestinalis* was used as a supplement for growth media with sea water chemical composition and effectively led to the exclusive isolation of *Acrostalagmus*, *Arthopyrenia*, *Cordyceps* and

Sporosarcina fungal species from the gut tissues of *C. intestinalis* [40]. Even though it was understood that different fungal species may have unique nutritional requirements as shown in some studies [40], it was beyond the scope of this study to investigate the response of fungal isolates to different culture media and growth conditions.

A total of 19 fungal cultures exhibited excellent growth on PDA and thus were prioritized for crude metabolite extraction using methanol. The crude extracts were tested *in vitro* for antimycobacterial activity against *M. smegmatis* mc²155 and *M. tuberculosis* H37Rv, and the minimum inhibitory concentrations (MICs) observed are listed in Table 3. According to Awouafack et al., the MIC of crude extracts are considered to be significant if they are below 0.1 mg/mL, moderate if between 0.1–0.625 mg/mL and weak if greater than 0.625 mg/mL [43]. The methanol extract from *C. rogersoniana* MGK33 therefore exhibited moderate activity against *M. smegmatis* mc²155 and *M. tuberculosis* H37Rv with MIC values of 0.125 and 0.20 mg/mL respectively. No data was found for antitubercular activity of *C. rogersoniana* extracts in literature to make comparisons. Methanol extracts from *Penicillium*, *Fusarium*, *Galactomyces*, *Geotrichum* and *Mucor* showed poor inhibitory activity against *M. smegmatis* mc²155 and *M. tuberculosis* H37Rv.

Poor activity from extracts of multiple fungi was unsurprising because *Mycobacteria* are known to possess intrinsic and extrinsic resistance to

Table 4. Unique metabolites identified from extracts of six selected fungi and their docking scores.

No.	Proposed ID	Predicted formula	Precursor m/z [M + H] ⁺	Err ppm	RT (min)	Docking scores (kcal/mol)*		
						1UZN	4Q8I	6P9K
<i>F. oxysporum</i> MGK13 metabolites								
1	Dehydrofusaric acid	C ₁₀ H ₁₁ NO ₂	178.0860	1.44	4.69	-4.80	-3.71	-2.62
2	Fusarinolic acid	C ₁₀ H ₁₃ NO ₃	196.0966	1.13	4.69	-6.01	-4.60	-5.06
3	Fusaric acid	C ₁₀ H ₁₃ NO ₂	180.1017	1.15	5.42	-5.40	-3.48	-3.64
4	3-Dehydrosphinganine	C ₁₈ H ₃₇ NO ₂	300.2885	4.03	11.49	-2.65	-2.85	-4.96
5	Beauvericin	C ₄₅ H ₅₇ N ₃ O ₉	784.4191	-2.99	11.92	-4.15	-1.49	-2.88
<i>M. circinelloides</i> MGK14 metabolites								
6	Pantothenic acid	C ₉ H ₁₇ NO ₅	220.1183	-1.60	4.69	-5.49	-1.68	-1.92
<i>C. eragrosticola</i> MGK20 metabolites								
7	L-Arginine	C ₆ H ₁₄ N ₄ O ₂	175.1188	0.87	0.72	-4.23	-4.44	-5.33
8	L-Phenylalanine	C ₉ H ₁₁ NO ₂	166.0859	2.15	4.57	-5.34	-3.77	-5.61
9	N-Acetylsphinganine	C ₂₀ H ₄₁ NO ₃	344.3154	1.52	9.06	-4.83	-4.57	-4.54
10	Sphingosine	C ₁₈ H ₃₇ NO ₂	300.2911	-4.66	11.40	-4.50	-3.63	-4.20
11	Antibiotic BK230	C ₅₇ H ₉₁ N ₉ O ₁₄	1126.678	-1.93	12.16	n.d.	n.d.	n.d.
<i>P. antarticum</i> MGK31 metabolites								
12	Arohynapene A	C ₁₈ H ₂₂ O ₃	287.1631	3.74	0.78	-6.87	-4.36	-5.59
13	Chrysogine	C ₁₀ H ₁₀ N ₂ O ₂	191.0812	1.60	5.31	-6.90	-5.27	-7.00
14	L-Phe-L-His	C ₁₁ H ₁₈ N ₄ O ₃	303.1452	-0.11	5.41	-7.37	-4.89	-4.96
15	Cyclo (L-Phe-L-Pro)	C ₁₄ H ₁₆ N ₂ O ₂	245.1286	-0.60	5.77	-6.02	-4.30	-5.06
16	Penicitrinol P	C ₁₆ H ₂₀ O ₆	309.1328	1.51	6.25	-5.43	-4.90	-4.67
17	Trans-Resorcylide	C ₁₆ H ₁₈ O ₅	291.1227	0.00	6.25	-6.20	-2.81	-6.16
18	Penexanthone B	C ₁₉ H ₂₀ O ₈	377.1257	-6.93	6.42	-5.32	n.d.	-4.78
19	Cladosporin	C ₁₆ H ₂₀ O ₅	293.1385	-0.51	8.17	-6.19	-4.80	-5.29
20	Penicisochroman A	C ₁₆ H ₁₈ O ₄	275.1273	1.80	8.17	-6.44	-4.53	-4.97
21	Antibiotic TAN 1446A	C ₁₇ H ₂₂ O ₅	307.154	0.00	9.60	-5.14	-3.85	-4.81
22	Chrysoeside C	C ₄₀ H ₇₃ NO ₉	712.5357	0.15	11.98	-5.69	-5.20	-5.59
<i>C. rogersoniana</i> MGK33 metabolites								
23	Gadusol	C ₈ H ₁₂ O ₆	205.0693	6.69	0.67	-6.22	-3.65	-4.67
24	Bionectin F	C₅₀H₉₆O₈	825.7189	-1.34	9.08	-11.17	-8.19	-8.94
25	C16 Phytosphingosine	C ₁₆ H ₃₅ NO ₃	290.2702	-4.25	7.85	-2.16	-1.15	-3.23
26	L-Ile-L-Pro	C ₁₁ H ₂₀ N ₂ O ₃	229.1556	-4.08	2.82	-5.30	-3.64	-4.81
27	L-Tryptophan	C ₁₁ H ₁₂ N ₂ O ₂	205.0977	-2.67	2.82	-6.46	-5.73	-4.55
28	L-Tyrosine	C ₉ H ₁₁ NO ₃	182.0810	0.94	1.67	-5.98	-5.24	-4.11
<i>P. expansum</i> MGK42 metabolites								
29	Dihydrovermistatin	C ₁₈ H ₁₈ O ₆	331.1161	4.59	0.78	-5.22	-2.82	-4.89
30	Sativan	C ₁₇ H ₁₈ O ₄	287.1266	4.14	0.78	-5.75	-4.24	-5.16
31	Canadensolide	C ₁₁ H ₁₄ O ₄	211.0957	3.74	5.22	-4.69	-3.85	-4.12
No.	Proposed ID	Predicted formula	Precursor m/z [M + H] ⁺	Err ppm	RT (min)	Docking scores (kcal/mol)*		
						1UZN	4Q8I	6P9K
<i>P. expansum</i> MGK42 metabolites								
32	Aurantioclavine	C ₁₅ H ₁₈ N ₂	227.1532	4.75	5.42	-4.05	-5.43	-5.36
33	Clavicipitic acid	C ₁₆ H ₁₈ N ₂ O ₂	271.1438	1.13	5.48	-6.59	-4.70	-5.77
34	Roquefortine C	C ₂₂ H ₂₃ N ₅ O ₂	390.1931	-1.67	5.75	-9.36	-3.48	-4.98
35	Roquefortine D	C ₂₂ H ₂₅ N ₅ O ₂	392.2077	1.03	5.76	-5.31	-3.66	-4.48
36	(16R)-Hydroxyroquefortine C	C ₂₂ H ₂₃ N ₅ O ₃	406.1877	-0.82	6.07	-5.80	-4.04	-4.98
37	Cyclo (L-Phe-L-Phe)	C ₁₈ H ₁₈ N ₂ O ₂	295.1449	-2.71	6.36	-6.05	-3.87	-6.08
38	Dehydrohistidyl-tryptophanyl-diketopiperazine	C ₁₇ H ₁₅ N ₅ O ₂	322.1298	0.16	6.37	-8.25	-6.13	-6.15
39	Communesin E	C ₂₇ H ₃₀ N ₄ O ₂	443.2454	-2.82	6.55	-5.60	-2.91	-5.37
40	Communesin 470	C ₂₇ H ₃₄ O ₇	471.2389	0.36	7.06	-6.25	-4.02	-5.17
41	24-Oxocyclocitrinol	C ₂₅ H ₃₄ O ₄	399.2537	-1.79	7.13	-6.03	-4.69	-5.36
42	Chaetoglobosin E	C ₃₂ H ₃₈ N ₂ O ₅	531.2850	0.66	7.50	-4.47	-3.25	-6.27
43	Communesin B	C ₃₂ H ₃₆ N ₄ O ₂	509.2880	6.10	7.50	-3.80	-2.66	-2.58
44	Citrinin	C ₁₃ H ₁₄ O ₅	251.0912	0.80	7.65	-5.80	-2.23	-5.02
45	Viridicatin	C ₁₅ H ₁₁ NO ₂	238.0862	0.23	7.65	-6.49	-4.75	-4.72
46	Chaetoglobosin A	C ₃₂ H ₃₆ N ₂ O ₅	529.2690	1.32	8.28	-5.73	-0.76	-4.03
47	Deformylcalbistrin A	C ₃₀ H ₄₀ O ₇	513.2877	-5.90	8.43	-5.32	-3.38	-4.49
48	Chaetoglobosin F	C ₃₂ H ₃₈ N ₂ O ₅	531.2851	0.47	8.43	-6.12	-1.35	-3.61

(continued on next page)

Table 4 (continued)

No.	Proposed ID	Predicted formula	Precursor m/z [M + H] ⁺	Err ppm	RT (min)	Docking scores (kcal/mol)*		
						1UZN	4Q8I	6P9K
49	Communesin D	C ₃₂ H ₃₄ N ₄ O ₃	523.2708	-0.83	8.49	-4.75	-2.80	-3.94
50	Andrastin A	C ₂₈ H ₃₈ O ₇	487.2703	-2.61	9.07	-4.66	n.d.	-1.45
51	Chaetoglobosin D	C ₃₂ H ₃₆ N ₂ O ₅	529.2690	1.32	9.10	-4.53	-2.88	-4.16
52	Cytoglobosin D	C ₃₂ H ₃₈ N ₂ O ₄	515.2919	-2.85	9.88	-7.14	-1.94	-4.37
53	Chaetoglobosin J	C ₃₂ H ₃₆ N ₂ O ₄	513.2749	-0.23	10.36	-5.96	-2.97	-4.44
54	Chrysogeseide A	C ₄₀ H ₇₃ NO ₉	712.5344	1.98	11.51	-5.99	-6.41	-6.71

*Abbreviations represent protein receptors as follows: **1UZN** = *M. tuberculosis* β -ketoacyl-acyl carrier protein reductase A (MabA); **4Q8I** = β -lactamase (Blac) and **6P9K** = β -ketoacyl-acyl carrier protein synthase (KasA). In the table, n.d. means not docked.

Table 5. Metabolites common to two or more fungal isolates and their molecular docking scores.

No.	Proposed ID	Predicted formula	Metabolite occurrence [‡]	Precursor m/z [M + H] ⁺	Err ppm	RT (min)	Docking scores (kcal/mol)*		
							1UZN	4Q8I	6P9K
55	Choline sulfate	C ₅ H ₁₃ NO ₄ S	MGK13	184.0633	1.67	0.78	-4.51	-3.94	-3.37
			MGK20	184.0629	4.95	0.78			
			MGK31	184.0633	2.76	0.78			
56	L-Carnitine	C ₇ H ₁₅ NO ₃	MGK13	162.1123	1.67	0.78	-4.13	-3.46	-3.69
			MGK14	162.1124	0.43	0.81			
			MGK20	162.1123	1.05	0.78			
			MGK31	162.1127	-1.43	0.78			
			MGK42	162.1117	4.78	0.78			
57	Adenosine	C ₁₀ H ₁₃ N ₅ O ₄	MGK20	268.1043	4.61	4.56	-6.77	-4.43	-4.45
			MGK33	268.1028	-1.01	2.06			
58	Cyclo (L-Leu-L-Pro)	C ₁₁ H ₁₈ N ₂ O ₂	MGK31	211.1441	0.02	5.62	-5.57	-4.78	-5.67
			MGK33	211.1448	-3.31	3.85			
59	Cyclo (L-Pro-L-Val)	C ₁₀ H ₁₆ N ₂ O ₂	MGK20	197.1287	-1.25	4.86	-5.92	-4.07	-5.55
			MGK31	197.1288	-1.76	5.18			
60	Pyridoxamine	C ₈ H ₁₂ N ₂ O ₂	MGK20	169.0970	0.92	4.59	-5.26	-5.30	-6.20
			MGK31	169.0970	0.92	4.88			
61	Phytosphingosine	C ₁₈ H ₃₉ NO ₃	MGK13	318.3001	0.54	7.71	-3.77	-2.72	-6.20
			MGK14	318.3000	0.85	7.68			
			MGK20	318.3007	-1.35	7.59			
			MGK31	318.2993	3.06	8.63			
			MGK42	318.2998	1.48	7.63			
62	Sphinganine	C ₁₈ H ₃₉ NO ₂	MGK13	302.3053	0.19	8.49	-4.21	-3.44	-3.95
			MGK14	302.3050	1.18	8.46			
			MGK20	302.3059	-1.81	8.37			
			MGK31	302.3046	2.51	8.60			
			MGK42	302.3045	2.84	8.40			
63	Citrospiosteroid	C ₂₈ H ₄₄ O ₄	MGK31	445.3283	6.61	12.12	-4.70	-2.43	-3.02
			MGK42	445.3310	0.53	11.96			
64	Chrysogeseide B	C ₄₁ H ₇₅ NO ₉	MGK31	726.5522	-1.02	12.53	-6.91	-6.63	-6.98
			MGK42	726.5524	-1.30	12.22			
65	Ergosta-4,6,8 (14),22-tetraen-3-one	C ₂₈ H ₄₀ O	MGK13	393.3153	-0.27	12.23	-5.13	-3.30	-4.80
			MGK31	393.3164	-3.08	12.49			

[‡] Abbreviations represent fungal isolates as follows: **MGK13** = *F. oxysporum* MGK13; **MGK14** = *M. circinelloides* MGK14; **MGK20** = *C. eragrosticola* MGK20; **MGK31** = *P. antarcticum* MGK31; **MGK33** = *C. rogersoniana* MGK33 and **MGK42** = *P. expansum* MGK42.

* Abbreviations represent protein receptors as follows: **1UZN** = *M. tuberculosis* β -ketoacyl-acyl carrier protein reductase A (MabA); **4Q8I** = β -lactamase (Blac) and **6P9K** = β -ketoacyl-acyl carrier protein synthase (KasA). In the table, n.d. means not docked.

many antibiotics currently available. Drug-resistance mechanisms utilized by *Mycobacteria* include the use of a thick, waxy and hydrophobic cell envelope on the pathogen's surface to limit penetration of compounds [44]. Drugs that may possibly make past the cell wall defense system may be met with degrading enzymes such as rifampin inactivating ADP ribosyltransferase, penicillin inactivating β -lactamase, erythromycin ribosome methyltransferase and aminoglycoside acetyltransferase [44, 45, 46]. Protein pumps such as the ATP-binding cassette (ABC)

transporters (e.g., Rv1819c, Rv0194, Rv0933, Rv1473, Rv2477c, etc.) are known to facilitate the efflux of β -lactams, macrolides, isoniazid, rifampicin and several other antibiotics [47].

Since some fungal secondary metabolite biosynthetic gene clusters (BGCs) are understood to be silent in standard culture conditions [48], activating these genes in fungal isolate cultures could promote the production of antimycobacterial compounds by the fungi. Some interesting techniques utilized in the stimulation of silent BGCs include the




Figure 2. Three-dimensional representation of the binding pocket of 1UZN docked with bionectin F (A), and the two-dimensional representation of the molecular interactions observed between bionectin F and the binding site residues of 1UZN docked (B).

co-culturing of fungi and *Mycobacteria* to promote cross-talk and activation of silent-pathways in fungi [49, 50]. In one study, researchers observed that there was selective production of aurasperone, desmethylkotanin, TMC-256A1 and malformin C by marine *Aspergillus niger* when co-cultured with *M. smegmatis* [51].

More recently, a CRISPR-based transcriptional activation methodology has been developed for filamentous fungi and promises to expand the exploration of silent genes in fungi [52]. Thus said, fungi which did produce bioactive extracts against *Mycobacteria* may very well have their BGC-induction studies re-explored to assess metabolites which are not observed in standard culture conditions that were used in this study.

3.3. Metabolite profiling of fungal isolates

Six fungal isolates which include *F. oxysporum* MGK13, *M. circinelloides* MGK14, *C. eragrosticola* MGK20, *P. antarcticum* MGK31, *C. rogersoniana* MGK33 and *P. expansum* MGK42 were prioritized for metabolite profiling using liquid chromatography quadrupole time-of-

flight tandem mass spectrometry (LC-QTOF-MS/MS) in positive mode. MSFinder was used to calculate molecular formulas for the detected $[M + H]^+$ ions. After manually searching in several public and subscription databases, peaks were annotated with predicted compound IDs as shown in Tables 4 and 5. Chemical structures of the identified compounds are available in Supplementary File 2.

Among the metabolites identified, a total of 55 metabolites were found to be unique (Table 4), and whose occurrence was observed in a single individual fungal isolate in this study. Of these unique metabolites, five were identified from the methanol crude extract of *F. oxysporum* MGK13 as follows: Dehydrofusaric acid (1), fusarinolic acid (2), fusaric acid (3), 3-dehydrospinganine (4) and beauvericin (5). Against *M. tuberculosis*, fusaric acid (2) at a concentration of 60 μ M was found to cause 14.9% growth inhibition [53], while beauvericin (5) exhibited a MIC of 0.8–1.6 mg/mL [54].

The weak antimycobacterial activity of fusaric acid (2) and beauvericin (5) help explain the poor activity observed from *F. oxysporum* MGK13 methanol crude extract in this study. Metabolites from




Figure 3. Molecular dynamics simulation analysis for the 1UZU-bionectin F complex. RMSD plots of the protein-ligand (1UZU and bionectin F) complex, ligand, and the protein back-bone for a 50 ns simulation (A). RMSF plot showing conformational fluctuations of the residues during the simulation, where interaction incidences are depicted by vertical green lines (B). The binding interactions of bionectin F with 1UZU during the simulation (C).

M. circinelloides MGK14 were very challenging to identify as there are a limited number of reports on pure compounds from the *Mucor* genus. Bioprospecting studies utilizing extracts from this genus are also rare. However, *M. circinelloides* has been reported to accumulate β -carotene (Vitamin A) [55], which perhaps explains the identification of pantothenic acid (Vitamin B5) (6) using the MS/MS fragmentation data of m/z 220.1183 $[M + H]^+$. *M. circinelloides* is also known to be an oleaginous fungus capable of producing γ -linolenic [56]. Among the metabolites identified from *C. eragrosticola* MGK20, two were amino acids, L-arginine (7) and L-phenylalanine (8). These naturally occurring amino acids participate in various metabolic processes in cells, and thus are not expected to possess antimicrobial effect.

Extracts from *P. antarcticum* MGK31 and *P. expansum* MGK42 had greatest number of database hits (compounds 12–22 and 29–54 respectively) as the *Penicillium* genus is one of the widely explored natural source of bioactive agents. It was interesting to observe that even though extracts from the *Penicillium*s evidently harbored chemically diverse metabolites, the extracts showed poor inhibition of *Mycobacterial*

growth in culture. This was not surprising as *Mycobacteria* are known to possess intrinsic resistance against a wide range of antibiotics as previously mentioned [44].

Metabolite profiling of the methanol extract from *C. eragrosticola* MGK20 resulted in the identification of gadusol (23), bionectin F (24), C16 phytosphingosine (25), L-Ile-L-Pro (26), L-Tryptophan (27) and L-Tyrosine (28). Among these compounds, the polyprenol polyterpenoid bionectin F (24) was first isolated from *Bionectria* sp. Y1085 (*Clonostachys* and *Bionectria* genera belongs to the Bionectriaceae family) [57]. Unfortunately, the researchers in the previously mentioned study did not investigate any bioactivity of bionectin F. C16 phytosphingosine is a fatty acid which belongs to the family of sphingolipids, compounds abundant in fungi, plants and animal [58]. Başıpınar et al., investigated the antimicrobial activity of commercially obtained phytosphingosine and found strong activity against *Enterococcus faecalis* (MIC = 4 μ g/mL) and *Bacillus subtilis* (MIC = 8 μ g/mL), but poor activity against *Pseudomonas aeruginosa*, *Salmonella enterica* and *Escherichia coli* (MIC \geq 1024 μ g/mL) [59]. Gadusol (23), a metabolite of fungi, algae, bacteria and animals [60],

plays a role as an ultra-violet (UV) photo-protectant that absorbs maximally at 268 nm in acidic pHs, and as an antioxidant [61, 62]. Reports on metabolites from *C. rogersoniana* are very limited and thus the majority of ion peaks could not be annotated with database IDs. Bioactivity-guided fractionation and purification may help to isolate and characterize previously unidentified pure compounds.

3.4. Molecular docking and molecular dynamics simulation of fungal metabolites

The *in silico* molecular docking study demonstrated that the investigated ligands interacted with active site residues of *M. tuberculosis* H37Rv target proteins (1UZN, 4Q8I, and 6P9K) with docking scores presented in Tables 4 and 5. The values of the docking scores revealed that bionectin F has the highest affinity to the selected target proteins (1UZN = -11.17 kcal/mol, 6P9K = -8.94 kcal/mol and 4Q8I = -8.19 kcal/mol). The molecular interactions of bionectin F with residues of the 1UZN and the binding pocket are both depicted in Figures 2A and 2B. The strong interaction of bionectin F with the critical binding cavity of 1UZN was through hydrogen bonding MET A:190, ASP A:189, ASP A:94, LYS A:157, ASN A:88, ASN A:24, ILE A:31 and LYC A:184. Hydrophobic residues in the binding cavity of 1UZN also interacted with bionectin F, thus contributing to the ligand's observed affinity. The 1UZN and bionectin F complex was selected for further analysis in molecular dynamics simulations because of the interestingly high docking affinity.

The 1UZN and bionectin F (protein-ligand) complex was subjected to 50 ns molecular dynamics simulations to virtually evaluate in real-time, the structural stability and dynamic behavior of the protein-ligand complex system. The molecular dynamics simulations also determined which amino acids residues of 1UZN interact with the atoms of the bionectin F. The stability of the bionectin F and 1UZN complex was analyzed from the root mean square deviation (RMSD) plot depicted in Figure 3. The RMSD trajectory of the bionectin F and 1UZN complex, sharply augmented from 0 Å to 2.8 Å from the onset until 6 ns, remained constant until around 38 ns and then gradually fluctuated around 2 Å and 2.5 Å. The RMSD of (1UZN) backbone gradually rose from 0 Å to around 2.8 Å from 0 ns until the end of the 50 ns simulation. The RMSD plots show that the bionectin F and 1UZN complex is stable and there were no significant conformational changes in the structure of bionectin F (ligand).

The systemic fluctuations along the 1UZN protein chain residues were analyzed based on the Root Mean Square Fluctuation (RMSF) plot presented in Figure 3A. The results showed low residual fluctuations in residues which interacted with the ligand while larger fluctuations were observed in residues which were not interacting with the ligand. Trajectory analysis of the 0–50 ns simulation showed that bionectin F was bound to the cavity of 1UZN through hydrogen bonds (24 residues), ionic interactions (6 residues), water bridges (36 residues) and hydrophobic interactions (13 residues) along Chain A (Figure 3B). After using CASTp to determine the binding pocket in 1UZN [63], it was noted that A:SER140 forms part of the substrate (β -ketoacyl-acyl carrier protein) binding site, while A:ASN88 and A:ILE186 form part of the binding site of the cofactor (NADPH) (Figure 3C). In a recent study, site-directed mutagenesis on A:SER140 led to complete loss of binding affinity for NADPH which is required by the enzyme to change the conformation of the apo-form with a “closed” active site to an open conformation in the holo-form [64, 65].

4. Conclusions

There is growing interest in discovering potent and novel antimycobacterial drugs which will overcome the limitations of presently used TB-drugs. Secondary metabolites from filamentous fungi have been regarded as an inexhaustible reservoir of diverse compounds for consideration in TB-drug discovery programs. In this study, the methanol crude extract from *C. rogersoniana* MGK33 was found to possess

considerable antimicrobial activity against *M. smegmatis* mc²155 and *M. tuberculosis* H37Rv, with MICs of 0.125 and 0.2 mg/mL respectively observed. *In silico* molecular docking studies which identified metabolites from *C. rogersoniana* MGK33 revealed that bionectin F is a potential inhibitor of *M. tuberculosis* β -ketoacyl-acyl carrier protein reductase (MabA), with the docking score observed as -11.17 kcal/mol. The analysis of the molecular dynamics simulations trajectories revealed that bionectin F interacted with the A:SER140, a substrate binding site residue of MabA. The antimycobacterial activity screening results and the molecular docking and molecular dynamics simulations led to the conclusion that bionectin F is a potential inhibitor of MabA, an essential protein in *M. tuberculosis*. Further work focused on the purification of bionectin F from *C. rogersoniana* MGK33 and the validating of *in silico* assays in this study should be performed.

Declarations

Author contribution statement

Vuyo Mavumengwana: Conceived and designed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Lucinda Baatjies: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Kudzana Ian Tapfuma: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Kudakwashe Nyambo: Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Rehana Malgas-Enus: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.

Liezel Smith, Nasiema Allie, Mkhuseleli Ngxande, Andre Gareth Loxton, Marshall Keyster: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.

Francis Adu-Amankwaah: Analyzed and interpreted the data; Wrote the paper.

Funding statement

Vuyo Mavumengwana was supported by National Research Foundation (UID129364).

Mr Kudzana Ian Tapfuma was supported by Deutscher Akademischer Austauschdienst France (91793243).

Data availability statement

Data associated with this study has been deposited at NCBI GenBank under the accession number MT738573-MT738604.

Declaration of interest's statement

The authors declare no competing interests.

Additional information

Supplementary content related to this article has been published online at <https://doi.org/10.1016/j.heliyon.2022.e12406>.

References

- [1] WHO, Global Tuberculosis Report 2021, World Health Organization, Geneva, 2021. <https://www.who.int/publications/i/item/9789240037021> (accessed May 30, 2021).
- [2] WHO, Tuberculosis (TB), World Health Organ. <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>, 2020 (accessed May 30, 2021).

- [3] TB Statistics, TBfacts.Org. <https://tbfacts.org/tb-statistics/>, 2022 (accessed October 18, 2022).
- [4] WHO, Global Tuberculosis Report 2020, World Health Organization, Geneva, 2020. <https://www.who.int/publications-detail-redirect/9789240013131> (accessed May 30, 2021).
- [5] H. Hong, C. Budhathoki, J.E. Farley, Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection, *Int. J. Tuberc. Lung Dis.* 22 (2018) 667–674.
- [6] W. Song, S. Si, The rare ethambutol-induced optic neuropathy, *Medicine* 96 (2017) e5889.
- [7] D. Karuppannasamy, A. Raghuram, D. Sundar, Linezolid-induced optic neuropathy, *Indian J. Ophthalmol.* 62 (2014) 497–500.
- [8] D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, D. Menzies, Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis, *Am. J. Respir. Crit. Care Med.* 167 (2003) 1472–1477.
- [9] I. Jeong, J.-S. Park, Y.-J. Cho, H.I. Yoon, J. Song, C.-T. Lee, J.-H. Lee, Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels, *J. Korean Med. Sci.* 30 (2015) 167–172.
- [10] D. Quan, G. Nagalingam, R. Payne, J.A. Triccas, New tuberculosis drug leads from naturally occurring compounds, *Int. J. Infect. Dis.* 56 (2017) 212–220.
- [11] K. Duarte, T.A.P. Rocha-Santos, A.C. Freitas, A.C. Duarte, Analytical techniques for discovery of bioactive compounds from marine fungi, *TrAC, Trends Anal. Chem.* 34 (2012) 97–110.
- [12] S.K. Deshmukh, V. Prakash, N. Ranjan, Marine Fungi: a source of potential anticancer compounds, *Front. Microbiol.* 8 (2018).
- [13] C. Wang, S. Tang, S. Cao, Antimicrobial compounds from marine fungi, *Phytochem. Rev.* 20 (2021) 85–117.
- [14] Marine Fungi, (n.d.). <https://www.marinefungi.org/> (accessed May 31, 2021).
- [15] E.A.M. El-Bondkly, A.A.M. El-Bondkly, A.A.M. El-Bondkly, Marine endophytic fungal metabolites: a whole new world of pharmaceutical therapy exploration, *Heliyon* 7 (2021), e06362.
- [16] D.J. Watters, Ascidian toxins with potential for drug development, *Mar. Drugs* 16 (2018) 162.
- [17] J.S. Evans, P.M. Erwin, N. Shenkar, S. López-Legentil, Introduced ascidians harbor highly diverse and host-specific symbiotic microbial assemblages, *Sci. Rep.* 7 (2017), 11033.
- [18] Q. Song, X.-M. Li, X.-Y. Hu, X. Li, L.-P. Chi, H.-L. Li, B.-G. Wang, Antibacterial metabolites from Ascidian-derived fungus *Aspergillus clavatus* AS-107, *Phytochem. Lett.* 34 (2019) 30–34.
- [19] A.N. Yurchenko, E.V. Ivanets, O.F. Smetanina, M.V. Pivkin, S.A. Dyshlovoi, G. von Amsberg, Sh.Sh. Afyatullof, Metabolites of the marine fungus *Aspergillus candidus* KMM 4676 associated with a Kuril colonial ascidian, *Chem. Nat. Compd.* 53 (2017) 747–749.
- [20] C. Wang, J. Wang, Y. Huang, H. Chen, Y. Li, L. Zhong, Y. Chen, S. Chen, J. Wang, J. Kang, Y. Peng, B. Yang, Y. Lin, Z. She, X. Lai, Anti-mycobacterial activity of marine fungus-derived 4-deoxybostrycin and nigrosporin, *Molecules* 18 (2013) 1728–1740.
- [21] A. Sharma, M.H. Islam, N. Fatima, T.K. Upadhyay, M.K.A. Khan, U.N. Dwivedi, R. Sharma, Elucidation of marine fungi derived anthraquinones as mycobacterial mycolic acid synthesis inhibitors: an *in silico* approach, *Mol. Biol. Rep.* 46 (2019) 1715–1725.
- [22] J. Hu, Z. Li, J. Gao, H. He, H. Dai, X. Xia, C. Liu, L. Zhang, F. Song, New diketopiperazines from a marine-derived fungus strain *Aspergillus versicolor* MF180151, *Mar. Drugs* 17 (2019) 262.
- [23] B.S. Havenga, Fouling by Non-indigenous marine Species – Impacts on Biodiversity and Mariculture, Stellenbosch University, 2014. <http://scholar.sun.ac.za/handle/10019.1/86742> (accessed November 23, 2021).
- [24] K.I. Tapfuma, N. Uche-Okerefor, T.E. Sebola, R. Hussan, L. Mekuto, M.M. Makatini, E. Green, V. Mavumengwana, Cytotoxic activity of crude extracts from *Datura stramonium*'s fungal endophytes against A549 lung carcinoma and UMG87 glioblastoma cell lines and LC-QTOF-MS/MS based metabolite profiling, *BMC Complement. Altern. Med.* 19 (2019) 330.
- [25] S. McGinnis, T.L. Madden, BLAST: at the core of a powerful and diverse set of sequence analysis tools, *Nucleic Acids Res.* 32 (2004) W20–W25.
- [26] R. Song, J. Wang, L. Sun, Y. Zhang, Z. Ren, B. Zhao, H. Lu, The study of metabolites from fermentation culture of *Alternaria oxytropis*, *BMC Microbiol.* 19 (2019) 35.
- [27] Y. Kanehiro, H. Tomioka, J. Pieters, Y. Tatano, H. Kim, H. Iizasa, H. Yoshiyama, Identification of novel mycobacterial inhibitors against mycobacterial protein kinase G, *Front. Microbiol.* 9 (2018) 1517.
- [28] M. Elshikh, S. Ahmed, S. Funston, P. Dunlop, M. McGaw, R. Marchant, I.M. Banat, Resazurin-based 96-well plate microdilution method for the determination of minimum inhibitory concentration of biosurfactants, *Biotechnol. Lett.* 38 (2016) 1015.
- [29] J.M. Andrews, Determination of minimum inhibitory concentrations, *J. Antimicrob. Chemother.* 48 (Suppl 1) (2001) 5–16.
- [30] K.I. Tapfuma, T.E. Sebola, N. Uche-Okerefor, J. Koopman, R. Hussan, M.M. Makatini, L. Mekuto, V. Mavumengwana, Anticancer activity and metabolite profiling data of *Penicillium janthinellum* KTM15, *Data Brief* 28 (2020) 104959.
- [31] T.P. Magangana, M.A. Stander, N.A. Masondo, N.P. Makunga, Steviol glycoside content and essential oil profiles of *Stevia rebaudiana* Bertoni in response to NaCl and polyethylene glycol as inducers of salinity and drought stress *in vitro*, *Plant Cell Tissue Organ Cult. PCTOC* 145 (2021) 1–18.
- [32] H. Tsugawa, T. Cajka, T. Kind, Y. Ma, B. Higgins, K. Ikeda, M. Kanazawa, J. VanderGheynst, O. Fiehn, M. Arita, MS-DIAL: Data Independent MS/MS deconvolution for comprehensive metabolome analysis, *Nat. Methods* 12 (2015) 523.
- [33] P. Mark, L. Nilsson, Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K, *J. Phys. Chem. A* 105 (2001) 9954–9960.
- [34] S. Chinnathambi, S. Karthikeyan, N. Hanagata, N. Shirahata, Molecular interaction of silicon quantum dot micelles with plasma proteins: hemoglobin and thrombin, *RSC Adv.* 9 (2019) 14928–14936.
- [35] T.B. Robinson, K. Peters, B. Brooker, Coastal invasions: the South African context, in: B.W. van Wilgen, J. Measey, D.M. Richardson, J.R. Wilson, T.A. Zengeya (Eds.), *Biol. Invasions South Afr.*, Springer International Publishing, Cham, 2020, pp. 229–247.
- [36] T. Gordon, L. Roth, F. Caicci, L. Manni, N. Shenkar, Spawning induction, development and culturing of the solitary ascidian *Polycarpa mytiligera*, an emerging model for regeneration studies, *Front. Zool.* 17 (2020) 19.
- [37] M. Baeza, S. Barahona, J. Alcañá, V. Cifuentes, Amplicon-metagenomic analysis of fungi from Antarctic terrestrial habitats, *Front. Microbiol.* (2017).
- [38] S.J. Biller, P.M. Berube, K. Dooley, M. Williams, B.M. Satinsky, T. Hackl, S.L. Hogle, A. Coe, K. Bergauer, H.A. Bouman, T.J. Browning, D. De Corte, C. Hassler, D. Hulston, J.E. Jacquot, E.W. Maas, T. Reinthaler, E. Sintes, T. Yokokawa, S.W. Chisholm, Marine microbial metagenomes sampled across space and time, *Sci. Data* 5 (2018), 180176.
- [39] A. Amend, G. Burgaud, M. Cunliffe, V.P. Edgcomb, C.L. Ettinger, M.H. Gutiérrez, J. Heitman, E.F.Y. Hom, G. Ianiri, A.C. Jones, M. Kagami, K.T. Picard, C.A. Quandt, S. Raghukumar, M. Riquelme, J. Stajich, J. Vargas-Muñiz, A.K. Walker, O. Yarden, A.S. Gladfelter, D.A. Garsin, Fungi in the marine environment: open questions and unsolved problems, *mBio* 10 (2019) e01189–18.
- [40] C. Utermann, V.A. Echemeyer, E. Oppong-Danquah, M. Blümel, D. Tasdemir, Diversity, bioactivity profiling and untargeted metabolomics of the cultivable gut microbiota of *Ciona intestinalis*, *Mar. Drugs* 19 (2021) 6.
- [41] S. López-Legentil, P.M. Erwin, M. Turon, O. Yarden, Diversity of fungi isolated from three temperate ascidians, *Symbiosis* 66 (2015) 99–106.
- [42] C.B.A. Menezes, R.C. Bonugli-Santos, P.B. Miqueletto, M.R.Z. Passarini, C.H.D. Silva, M.R. Justo, R.R. Leal, F. Fantinatti-Garborggini, V.M. Oliveira, R.G.S. Berlinck, L.D. Sette, Microbial diversity associated with algae, ascidians and sponges from the north coast of São Paulo state, Brazil, *Microbiol. Res.* 165 (2010) 466–482.
- [43] M.D. Awouafack, L.J. McGaw, S. Gottfried, R. Mbouangouere, P. Tane, M. Spittler, J.N. Eloff, Antimicrobial activity and cytotoxicity of the ethanol extract, fractions and eight compounds isolated from *Eriosema robustum* (Fabaceae), *BMC Complement. Altern. Med.* 13 (2013) 289.
- [44] S.M. Gygli, S. Borrell, A. Trauner, S. Gagneux, Antimicrobial resistance in *Mycobacterium tuberculosis*: mechanistic and evolutionary perspectives, *FEMS Microbiol. Rev.* 41 (2017) 354–373.
- [45] J. Baysarowich, K. Koteva, D.W. Hughes, L. Ejim, E. Griffiths, K. Zhang, M. Junop, G.D. Wright, Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr, *Proc. Natl. Acad. Sci.* 105 (2008) 4886–4891.
- [46] F. Sanz-García, E. Anoz-Carbonell, E. Pérez-Herrán, C. Martín, A. Lucía, L. Rodrigues, J.A. Ainsa, Mycobacterial aminoglycoside acetyltransferases: a little of drug resistance, and a lot of other roles, *Front. Microbiol.* 10 (2019) 46.
- [47] D. Machado, E. Lecorche, F. Mougari, E. Cambau, M. Viveiros, Insights on *Mycobacterium leprae* efflux pumps and their implications in drug resistance and virulence, *Front. Microbiol.* 9 (2018) 3072.
- [48] T. Boruta, Uncovering the repertoire of fungal secondary metabolites: from Fleming's laboratory to the International Space Station, *Bioengineered* 9 (2018) 12–16.
- [49] H.A. Tomm, L. Ucciferri, A.C. Ross, Advances in microbial culturing conditions to activate silent biosynthetic gene clusters for novel metabolite production, *J. Ind. Microbiol. Biotechnol.* 46 (2019) 1381–1400.
- [50] K.P.T. Silva, P. Chellamuthu, J.Q. Boedicker, Quantifying the strength of quorum sensing crosstalk within microbial communities, *PLoS Comput. Biol.* 13 (2017) 1–16.
- [51] T. Jomori, Y. Hara, M. Sasaoka, K. Harada, A. Setiawan, K. Hirata, A. Kimishima, M. Arai, *Mycobacterium smegmatis* alters the production of secondary metabolites by marine-derived *Aspergillus niger*, *J. Nat. Med.* 74 (2020) 76–82.
- [52] L. Mózsik, M. Hoekzema, N.A.W. de Kok, R.A.L. Bovenberg, Y. Nygård, A.J.M. Driessen, CRISPR-based transcriptional activation tool for silent genes in filamentous fungi, *Sci. Rep.* 11 (2021) 1118.
- [53] C.S. Emani, M.J. Williams, L.J. Wiid, B. Baker, C. Carolis, Compounds with potential activity against *Mycobacterium tuberculosis*, *Antimicrob. Agents Chemother.* 62 (2018) e02236-17.
- [54] C. Nilanonta, M. Isaka, P. Kittakoop, S. Trakulnaleamsai, M. Tanticharoen, Y. Thebtaranonth, Precursor-directed biosynthesis of beauvericin analogs by the insect pathogenic fungus *Paecilomyces tenuipes* BCC 1614, *Tetrahedron* 58 (2002) 3355–3360.
- [55] T. Naz, S. Nosheen, S. Li, Y. Nazir, K. Mustafa, Q. Liu, V. Garre, Y. Song, Comparative Analysis of β -carotene production by *Mucor circinelloides* strains CBS 277.49 and WJ11 under light and dark conditions, *Metabolites* 10 (2020).
- [56] X. Tang, L. Zhao, H. Chen, Y.Q. Chen, W. Chen, Y. Song, C. Ratledge, Complete genome sequence of a high lipid-producing strain of *Mucor circinelloides* WJ11 and comparative genome analysis with a low lipid-producing strain CBS 277.49, *PLoS One* 10 (2015) 1–11.
- [57] Y.-H. Yang, D.-S. Yang, G.-H. Li, X.-J. Pu, M.-H. Mo, P.-J. Zhao, Antibacterial diketopiperazines from an endophytic fungus *Bionectria* sp. Y1085, *J. Antibiot.* 72 (2019) 752–758.
- [58] A. Singh, M. Del Poeta, Sphingolipidomics: an important mechanistic tool for studying fungal pathogens, *Front. Microbiol.* 7 (2016) 501.
- [59] Y. Baspinar, M. Kotmakçı, İ. Öztürk, Antimicrobial activity of phytosphingosine nanoemulsions against bacteria and yeasts, *Celal Bayar Univ. J. Sci.* 14 (2018) 223–228.

- [60] A.R. Osborn, K.H. Almabruk, G. Holzwarth, S. Asamizu, J. LaDu, K.M. Kean, P.A. Karplus, R.L. Tanguay, A.T. Bakalinsky, T. Mahmud, De novo synthesis of a sunscreen compound in vertebrates, *Elife* 4 (2015).
- [61] D.E. Orallo, N.J. Loes, E.M. Arbeloa, S.G. Bertolotti, M.S. Churio, Sensitized photo-oxidation of gadusol species mediated by singlet oxygen, *J. Photochem. Photobiol., B* 213 (2020), 112078.
- [62] E.M. Arbeloa, M.J. Uez, S.G. Bertolotti, M.S. Churio, Antioxidant activity of gadusol and occurrence in fish roes from Argentine Sea, *Food Chem.* 119 (2010) 586–591.
- [63] W. Tian, C. Chen, X. Lei, J. Zhao, J. Liang, CASTp 3.0: computed atlas of surface topography of proteins, *Nucleic Acids Res.* 46 (2018) W363–W367.
- [64] L.A. Rosado, R.A. Caceres, W.F. de Azevedo, L.A. Basso, D.S. Santos, Role of Serine140 in the mode of action of *Mycobacterium tuberculosis* β -ketoacyl-ACP reductase (MabA), *BMC Res. Notes* 5 (2012) 526.
- [65] T. Küssau, M. Flipo, N. Van Wyk, A. Viljoen, V. Olieric, L. Kremer, M. Blaise, Structural rearrangements occurring upon cofactor binding in the *Mycobacterium smegmatis* β -ketoacyl-acyl carrier protein reductase MabA, *Acta Crystallogr. Sect. Struct. Biol.* 74 (2018) 383–393.